The past decade has produced genuine advances in cancer treatment. Immunotherapy has transformed outcomes for patients with melanoma and certain lung cancers. Targeted therapies have turned some diagnoses that were once rapidly fatal into conditions that can be managed over years. These are not marginal gains, and they should not be understated.
But the number of new cancer cases being diagnosed in England each year has now reached record levels, approaching 400,000 annually, and the pressure that volume places on the system is beginning to expose a structural problem that better drugs alone cannot fix. Too many patients are still being diagnosed at Stage III or IV, when the disease has already spread and treatment is both more demanding and less likely to succeed. Survival improvements have been real, but the data suggests they are starting to plateau, and the reason is not that medicine has run out of ideas. It is that medicine is being asked to do work that earlier detection could have prevented.
The arithmetic of stage at diagnosis is stark. Five-year survival for bowel cancer caught at Stage I is around 90 per cent. Caught at Stage IV, it falls below 10 per cent. Similar gradients exist across most major cancer types. A system that reliably identifies cancer earlier does not just save individual lives; it reduces the overall burden of treatment, shortens the length and intensity of care pathways, and frees capacity for other patients. The case for investing in earlier detection is clinical, financial and operational simultaneously.
The most promising shift in screening policy is the move away from age-based population programmes toward risk-stratified approaches. The targeted lung health check programme, which invites former and current heavy smokers for low-dose CT scans rather than waiting for symptoms, is the clearest domestic example. Early evaluations have shown it detects cancers predominantly at Stage I, where they would not otherwise have been found for months or years. Expanding that logic to other cancer types, using family history, genetic risk factors and lifestyle data to identify who most needs to be screened and when, represents a more efficient use of limited diagnostic resource than blanket age thresholds.
Multi-cancer early detection blood tests, which can screen for signals associated with dozens of cancer types from a single sample, are moving through clinical evaluation. The NHS-Galleri trial has been running in England and results are awaited. If the technology proves sufficiently sensitive and specific at a population level, it could change the architecture of cancer detection more substantially than any single treatment advance in recent memory. That is not a certainty, but it is a serious possibility that warrants the investment in evaluation currently being made.
The barriers to progress are not primarily scientific. Diagnostic capacity is constrained by workforce. There are not enough radiologists to read the scans a significantly expanded screening programme would generate, nor enough endoscopists to handle the colonoscopies that a successful bowel screening programme requires. Training takes years, and the workforce plan has been persistently optimistic about how quickly gaps can be filled. Without a credible solution to that bottleneck, expanding screening eligibility without expanding the people and equipment needed to deliver it creates a different kind of delay rather than eliminating one.
Uptake is the other problem, and it is unevenly distributed. Screening participation is lower in deprived communities and among certain ethnic minority groups than in the general population. The reasons are multiple, including distrust of health institutions, language barriers, practical difficulties in taking time off work, and fatalism about diagnosis. A screening programme that is technically available but culturally inaccessible does not deliver its potential. Closing the participation gap requires sustained outreach, translated materials, flexible appointment systems and community-based engagement, none of which is expensive relative to the cost of treating late-stage disease, but all of which require consistent funding and attention.
The record diagnosis figures are sometimes presented as a success story, reflecting improved awareness and better access to testing. In part, that is true. But they also reflect a system that catches too much disease too late. Rebalancing investment toward the front end of the cancer pathway is the area where the survival curve still has meaningful room to move.
